220 Million Dollar Investment Evonik Holds Groundbreaking Ceremony for New Lipids Production Facility

Source: Press release Ahlam Rais Reading Time: 2 min

Related Vendors

Evonik recently held a groundbreaking ceremony for the establishment of a large-scale lipids production facility in Lafayette, Indiana, USA. The new unit aims to offer critical excipients for the development of mRNA vaccines and other nucleic acid therapies.

The total investment into the commercial-scale lipid facility amounts to 220 million dollars.
The total investment into the commercial-scale lipid facility amounts to 220 million dollars.
(Source: Evonik)

Essen/Germany – Evonik has officially begun construction of its 220 million dollar global-scale production facility for pharmaceutical specialty lipids in Lafayette, Indiana, in the United States. The new facility is expected to secure the industry’s access to critical excipients needed for mRNA vaccines and other nucleic acid therapies. The plant is scheduled to go onstream in 2025.

“Our new Lipid Innovation Center will secure the health innovations of tomorrow. Through this investment, we reinforce our leading position in the pharmaceutical industry. We are privileged to support the U.S. with pandemic preparedness and enable the development of cutting-edge medicines,” said Christian Kullmann, CEO of Evonik.

“This new world-scale facility will enhance Evonik’s unique position as a CDMO in the pharmaceutical industry. Be it development quantities or large scale, be it formulation or fill-finish – our partners in the RNA drug space can rely on us along the entire process,” said Johann-Caspar Gammelin, president of the Nutrition & Care division at Evonik.

The total investment into the commercial-scale lipid facility amounts to 220 million dollars. The U.S. Government has entered a cooperative agreement with Evonik for a cost share of up to 150 million dollars through its Biomedical Advanced Research and Development Authority (Barda), a component of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS). Barda coordinated acquisition assistance with the Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).

Evonik’s Lipid Innovation Center will be built on the grounds of Evonik Tippecanoe Laboratories, which is one of the world’s largest contract manufacturing facilities for active pharmaceutical ingredients (APIs) and Evonik's second-largest site in the U.S. The new flexible development and manufacturing facility will allow for the rapid scale up and manufacturing of a variety of specialty lipids following high quality standards to serve future applications of RNA technology in infectious disease control, cancer immunotherapy, protein replacement, and gene therapy.

The groundbreaking ceremony for the Indiana-based Lipid Innovation Center on March 29, 2023, was attended by representatives of the federal government, the Governor of Indiana, Eric Holcomb, and local officials of the greater Lafayette area, who joined Evonik’s CEO Christian Kullmann and members of the company’s Management and Supervisory Board.


Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent